No prior treatment with TIP with the exception when given as a bridge to treatment on protocol for patients with rapidly progressive disease who cannot wait to complete the eligibility screening process; only one cycle is allowed
Progressive disease during or after treatment with at least one of the agents listed above
Subjects with CNS disease must have been on a stable dose of steroids for  weeks prior to their biopsy and must not have progressive hydrocephalus at enrollment.
Early or confirmed evidence of progressive disease.
Patients with rapidly progressive intermediate or high grade NHL
Progressive disease in the setting of medical or surgical castration (i.e., CRPC)
Rapidly progressive disease.
Patients must have at least ONE of the following: ) Recurrent/progressive disease at any time prior to study enrollment, ) Refractory disease, ) Persistent disease
Patients with progressive extracranial disease will not be excluded
Patients may have progressive systemic disease
Patients with clinical progression but without radiographically recurrent or radiographically progressive disease
Are progressive.
Hyperleukocytosis (>= , blasts/uL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
Participants with progressive systemic malignancy
Progressive disease defined by RECIST criteria =<  months
Progressive disease before initiating study treatment
TREATMENT EXCLUSION: Subjects with rapidly progressive disease, defined as kinetic failure to previous chemotherapy
Patients must not have experienced confirmed progressive disease since the time of their transplant
Any episode of progressive disease during aggressive multi-drug frontline therapy.
Progressive disease and no effective therapy exists
Hyperleukocytosis (>= , blasts/uL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
Progressive disease (AD worse) in non-risk organs after  weeks (Initial Course
Patients with progressive disease in risk organs
Unstable or rapidly progressive disease, including patients who require glucocorticoids for symptomatic control of brain or spinal tumors
Patients with rapidly progressive disease (PD) unresponsive to reinduction chemo, radio, or immunotherapy are ineligible.
Progressive disease following at least one first line standard therapy.
Patients must have progressive disease at study entry
At least one symptomatic and/or progressive liver lesion over a period of up to  months
Hyperleukocytosis (? , blasts/uL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
Primary ibrutinib resistance, defined by progressive disease within the first  months of first initiating ibrutinib therapy
Current medical need for therapy due to disease-related symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease.
Rapidly progressive symptoms of mCRPC.
Progressive underlying malignant disease or any post-transplant lymphoproliferative disease
ARM I EXCLUSION CRITERIA: Any evidence of progressive systemic disease (by RECIST .); those with stable systemic lesion(s) may be considered for enrollment
Has any evidence of progressive systemic disease (by RECIST .); those with stable systemic lesion may be considered for enrollment
Patients with rapidly progressive intermediate or high grade NHL
Patients must have evidence of progressive disease
Progressive disease at study entry defined as  or more of the following  criteria:
Chemotherapy (chemo)-resistant (defined by stable disease [SD] or progressive disease [PD] to most recent chemo regimen)
If the diagnosis is MPN-AP/BP, must have progressive/resistant disease after treatment with a DNMT inhibitor therapy (azacytidine, decitabine) as determined by the treating investigator
Progressive disease (PD) as best response to first-line therapy
Evidence of progressive MM compared to pretransplant evaluation (Cohort C)
Patients may not be less than  weeks from radiation therapy, unless progressive disease outside of the radiation field or  progressive scans at least  weeks apart or histopathologic confirmation
No more than three progressive sites of disease, with at least one of the disease sites to be deemed suitable for treatment with MRI-guided, online adaptive SBRT to the non-liver abdomen as per radiation oncology evaluation
Requirement for therapy of the hematological malignancy due to disease-related symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease.
Patients with progressive disease at time of transplant
Subjects must have received  or more prior therapies for this disease and have had stable disease or progressive disease based upon the criteria from the Revised Response Criteria for Malignant Lymphoma, or intolerable toxicities precluding further therapy with a prior regimen
Progressive disease despite ongoing androgen deprivation or chemotherapy. Progressive disease is defined by  or more of the following criteria:
Patients must have progressive metastatic disease defined as new or progressive lesions on cross-sectional imaging
Subjects must have received frontline standard therapy for high-risk neuroblastoma and meet one of the following three conditions for recurrent/progressive, refractory, or persistent disease\r\n* Recurrent/progressive disease at any time prior to enrollment (regardless of overall response to frontline therapy)\r\n* Refractory disease: persistent sites of disease after achieving a best overall response of stable disease to frontline therapy after a minimum of  cycles of induction therapy AND patient has never had recurrent/progressive disease\r\n* Persistent disease: persistent sites of disease after achieving a best overall response of partial response to frontline therapy after a minimum of  cycles of induction therapy AND patient has never had recurrent/progressive disease
Within  weeks of chemoradiation unless the patient fulfills criteria for early progressive disease by RANO
Intermediate or high grade NHL, mantle cell NHL, and Hodgkin disease that is progressive on salvage therapy; stable disease is acceptable to move forward provided it is non-bulky
Group I: KS requiring systemic therapy (no prior therapy required) and:\r\n* Group I patients should have one or more of the following:\r\n** T KS, KS on skin sufficiently widespread that it is not amenable to local therapy, or KS affecting quality of life due to local symptoms or psychological distress\r\n** KS patients with an inadequate response to pomalidomide (either progressive disease or stable disease requiring additional therapy after  months)\r\n** KS patients with an inadequate response to liposomal doxorubicin, paclitaxel, or other systemic chemotherapy (either progressive disease or stable disease requiring additional therapy after  cycles)\r\n* Group I will exclude patients eligible for Group II (below); patients with a history of multicentric Castleman disease (MCD) in the absence of any active disease (as assessed by the PI) are eligible for Group I\r\n* A wash out period off treatment of  weeks will be required, except in the case of patients with progressive, severe disease in which delay of treatment cannot be justified (i.e. symptomatic pulmonary KS)
Patients who have progressive disease or relapse (as defined by the IWCLL criteria) at or any time before registration on this study
Less than  weeks from radiation therapy, unless progressive disease outside of the radiation field or  progressive scans at least  weeks apart or histopathologic confirmation
Must not have a rapidly progressive disease
Subjects with uncontrolled distantly metastatic disease per RECIST criteria (progressive disease) on imaging following chemotherapy
Progressive hemato-lymphoid malignancy despite conventional therapy
No evidence of progressive disease on lenalidomide
Evidence of progressive disease on lenalidomide maintenance as per IMWG criteria
Progressive disease
Progressive disease or sites of new metastasis after definitive therapy for oligometastatic disease
Less than  weeks from radiation therapy, unless progressive disease outside of the radiation field or  progressive scans at least  weeks apart or histopathologic confirmation
Recurrent/progressive disease at any time
First episode of progressive disease during aggressive multi-drug frontline therapy.
Progressive disease (PD)
There is no limit as to the number or type of prior drug treatments but patients must have radiographic evidence of progressive disease
Rapidly progressive disease that in the estimation of the treating physician would compromise ability to complete study therapy
Progressive disease at transplant work-up
Patients must not have any evidence of progressive disease at the time of study entry
Current progressive disease, as defined by RECIST v.
Patients without confirmed progressive and/or refractory SM using standard RECIST criteria, or those with confirmed progressive and/or refractory SM using standard RECIST criteria.
Greater than  months from confirmed progressive disease on Study IPI--
Progressive disease at study enrollment.
Progressive disease (PD) documented by imaging or clinical findings less than or equal to  calendar months after cessation of previous anti-EGFR mAb treatment
Patients must have at least ONE of the following: ) Recurrent/progressive disease at any time prior to study enrollment, ) Refractory disease, ) Persistent disease
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Scan within  days prior to initiation of study vaccinations shows no evidence of progressive disease prior to study vaccination initiation based on the Response Assessment in Neuro-Oncology (RANO) criteria; participant with progressive disease after radiation therapy will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced
The subject must have progressive disease following at least one prior line of hormonal or chemotherapy for treatment of their metastatic disease
Intermediate or high grade NHL, mantle cell NHL, and Hodgkins disease that is progressive on salvage therapy; stable disease is acceptable to move forward provided it is non-bulky
Progressive disease at the time of enrollment
No rapidly progressive disease
At screening, patients may be included if the largest lesion is >  cm or >  in number, and there is no evidence of progressive CNS disease on brain imaging at least  days after treatment with surgery and/or radiation therapy
At screening, patients may be included if the largest lesion is >  cm or >  in number, if the patient has underdone treatment with surgery and/or radiation therapy and there is no evidence of progressive CNS disease on brain imaging at least  days after treatment
Hyperleukocytosis (>= , blasts/uL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
Patients must have progressive disease
Patients who at the discretion of the investigator are deemed to have rapidly progressive disease
Patients must have had progressive disease on, after, or refused, appropriate approved therapy for their tumor type.
Progressive disease during or after last treatment regimen.
Prior treatment for lymphoid malignancy requiring treatment for progressive disease
Must have achieved at least a stable disease (SD) for at least  cycle of treatment to at least  prior anti-myeloma regimen before developing Progressive disease (PD) (relapsed)
Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
Progressive disease within  months after completion of curatively intended treatment for locoregionally advanced SCCHN.
Documented progressive metastatic CRPC will be based on at least one of the following criteria:
EXCLUSION FOR TREATMENT: Rapidly progressive disease that in the estimation of the treating physician would compromise ability to complete study therapy
Radiologic evidence of progressive disease (according to [RECIST Version .) either during or within  months after stopping their most recent systemic therapy for RCC before enrollment into this study.
Patients must have progressive disease defined as at least one of the following:
Patients must have at least stable disease (no overt progressive disease) at the time of study registration
COHORT  ONLY (UROTHELIAL PROGRESSIVE DISEASE)
Patients must have progressive metastatic disease; progressive will be defined as new or progressive lesions on cross-sectional imaging
Patients must have progressive metastatic disease; progressive disease will be defined as new or progressive lesions on cross-sectional imaging
Widespread progressive disease, i.e., more than three sites of progressive disease (note that more than three sites of disease are permitted provided there are no more than three sites of progressive disease)
Evidence of progressive disease within  months of study entry
Evidence of recurrent or progressive underlying malignant disease
Evidence of recurrent or progressive underlying malignant disease
Progressive systemic disease
MRI post radiation therapy (RT) does not show progressive disease at time of randomization
Has progressive disease (PD) within six () months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC
Progressive underlying malignant disease including post-transplant lymphoproliferative disease.
Patients must have progressive or active disease following prior therapy for their myeloma which:
Progressive disease on prior treatment
Was not removed from carfilzomib therapy for progressive disease nor experienced progressive disease within  months after any prior carfizolmib therapy
Documented, progressive disease/tumor growth, which may include after exposure to a platinating agent (e.g. cisplatin or carboplatin) or another cytotoxic chemotherapy or radiation in a prior line of therapy, or documented intolerance to such an agent; prior line of therapy may include induction chemotherapy or chemoradiotherapy, in addition to treatment for recurrent/metastatic disease; de novo metastatic disease is also allowed as long as progressive disease/evidence of tumor growth is documented
Progressive disease during preoperative systemic therapy
Patients must have progressive disease within the thirteen months prior to study enrollment; progressive disease is as defined in Response Evaluation Criteria in Solid Tumors (RECIST) ., which is at least a % increase in the sum of diameters of target lesions and the sum must also demonstrate an absolute increase of at least  mm; the appearance of one or more new lesions is also considered progressive disease
Require immediate treatment for progressive CTCL
Rapidly progressive disease as judged by the investigator (examples include rapidly deteriorating performance status or symptomatic lymphangitic spread)
All patients must have progressive disease for which craniotomy and tumor resection is recommended as treatment
Progressive Disease (PD) following standard chemoradiation
Patients who have had prior cranial surgery are eligible, provided that there is evidence of measurable residual or progressive lesions, and at least  weeks have passed since surgery; if a patient has surgical resection followed by WBRT, then there must be evidence of progressive CNS disease after the completion of WBRT
Must have evidence of progressive disease within  months of study entry
Patients must have completed standard radiation therapy with concurrent TMZ and must not have evidence of progressive disease on post treatment imaging
Documented fungal disease that is progressive despite treatment
I . Progressive disease while receiving hormonal therapy or after surgical castration.
Currently has no evidence of progressive disease, as determined by the investigator, following previous treatment with GSK (either as monotherapy or as part of a combination treatment regimen)
Patients with rapidly progressive intermediate or high grade NHL
Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bony disease
Patient who shows evidence of progressive disease during salvage chemotherapy or following ASCT
in the opinion of the Investigator, the subject does not have progressive disease
Rapidly progressive disease.
Patients who were determined to have a best clinical response of progressive disease with salvage treatment immediately prior to ASCT
For pigmented villo-nodular synovitis (PVNS), patients must have a histologically confirmed diagnosis of inoperable progressive or relapsing PVNS, or resectable tumor requesting mutilating surgery, as well as demonstrated progressive disease in the last  months.
Patients must have relapsing disease (patients with progressive disease will be excluded); in addition, patients must have had at least two relapses in the past  months; relapses are defined clinically or radiographically
Patients who have progressive disease (PD) but have experienced \clinical benefit\ as defined in the study protocol
Patients with aggressive lymphomas (such as DLBC) must not have bulky, rapidly progressive disease immediately prior to HCT
Patients must have at least ONE of the following: ) Recurrent/progressive disease at any time prior to study enrollment, ) Refractory disease, ) Persistent disease
Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
Have progressive disease at the time of transplant
No progressive disease at the time of initiation of maintenance therapy
Progressive disease after ?  prior chemotherapy regimen.
The patient must have a life expectancy of  months or more based on the judgment of the investigators; women who have rapidly progressive symptomatic disease affecting major organ systems such as the liver and lungs will be excluded
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Documented progressive disease based on radiographic, clinical or pathologic assessment.
Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
Progressive disease while receiving a BTKi therapy, or stable disease as best response after  months of receiving a BTKi therapy
Systemic chemotherapy less than  days prior; however treatment may start earlier if there is evidence of rapidly progressive disease if approved by the principal investigator
Investigational agents within  days of dosing; however treatment may start earlier if there is evidence of rapidly progressive disease if approved by the principal investigator
Patients with any history of brain or bone metastasis or who have developed progressive disease on first line -FU based therapy
No evidence of progressive disease following completion of first-line chemotherapy (i.e., ongoing CR, PR, or SD per RECIST v. guidelines )
Progressive disease without any standard therapies established
Progressive disease after temozolomide and radiation therapy (in \first relapse\)
Widespread progressive disease, i.e., more than  sites of progressive disease (more than  sites of disease are permitted provided there are no more than  sites of progressive disease)
Confirmed progressive disease within  months of enrollment on study
Patients who have not had resection of recurrent or progressive disease must have measurable disease.
Patients must have received at least one prior anticancer regimen for metastatic disease unless there is no other therapy available and evidence of progressive disease on study entry. Patients with stable disease will be included if there has been failure to respond to another drug(s) within the previous  months
Patients are also considered to have progressive disease when:\r\n* New bone or soft tissue lesions (eg, plasmacytomas) are identified; or\r\n* There is an unequivocal increase in the size of previously existing lesions; or\r\n* The development of an otherwise unexplained serum calcium > . mg/dL is also a marker of progressive disease (PD)
Diagnosis of pneumonia defined as presence of a new or progressive infiltrate(s) on chest radiograph
progressive disease while receiving an AI for metastatic disease
Patient must have documented progressive disease within  months of his/her most recent cycle of chemotherapy
Progressive disease or marked splenomegaly and/or lymphadenopathy.
Patient has evidence of progressive disease while receiving iniparib.
Progressive disease within three months of completion of curatively intended treatment for locoregionally advanced or metastatic HNSCC
Refractory is defined as experiencing less than minimal response (MR) to or progressive disease (PD) within  days after completion of the most recent anti-MM regimen
Metastatic progressive CRPC defined as progressive disease despite surgical castration or ongoing use of gonadotropin-releasing hormone agonists with confirmed castrate levels of testosterone
Documented relapse or progressive disease on or after any regimen
For subjects who are deemed to be eligible for high-dose interleukin- (IL-) and elect to receive this therapy, such subjects must have progressive disease post-IL- to enter this study; such subjects must also have received and have had progressive disease after therapy with one of the agents listed
Persistent or progressive cancer following the completion of the standard therapy phase of the trial will not, in and of itself, preclude receipt of immunotherapy; however, patients will not receive immunotherapy if they have an ECOG performance status of  or  or, for children =<  years of age, Lansky =< ; furthermore, patients will be removed from the trial if they develop requirements for anti-neoplastic therapy (e.g. radiation therapy) for progressive disease during the trial
Progressive disease after medical or surgical castration,
Patients should have any of the following disease status: a. responsive or stable disease on salvage chemotherapy or radiation therapy; b. untreated, smoldering (i.e. not rapidly progressive) relapses
Progressive disease after treatment with single-agent nivolumab
Patients who show progressive disease or are not tolerating the current chemotherapy regimen
Progressive cancer (must be considered no evidence of disease or stable)
For stage IV disease, patients may be receiving no treatment or may be receiving maintenance treatment with a target agent, chemotherapy, or immunotherapy provided the most recent imaging does not demonstrate progressive disease
Progressive cancer (must be considered no evidence of disease or stable)
Evidence of progressive disease as compared to pre-HCT (persistence of disease is permitted)
Progressive malignancy
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Patient must have no evidence of progressive disease on restaging imaging within  months of enrollment
Patient must not have evidence of progressive disease
Evidence of progressive disease at the time of study enrollment
Patients with active, progressive or advanced disease based on diagnosis
A radiological diagnosis of recurrent/relapsed or progressive disease according to RANO criteria.
For cohort  only: progressive disease (PD) on lenvatinib per RECIST . =<  days prior to registration, as confirmed by the site study PI
Progressive disease manifest (within  weeks of screening) by either
Patients must have currently progressive metastatic disease according to RECIST v.\n             criteria, AND
Stable disease (duration of stable disease must be less than or equal to  months) or progressive disease as best response to most recent chemotherapy containing regimen
Progressive disease post-surgical castration or during androgen suppression therapy (pre-secondary hormone CRPC) OR
Primary ibrutinib resistance, defined by progressive disease within the first  months of first initiating ibrutinib therapy
